Overview: Oligonucleotides are an emerging class of DNA and RNA therapeutics that address a number of unmet medical needs. As with many biopharmaceuticals, the complex structure of oligonucleotides makes their large-scale synthesis both challenging and imperfect.
A number of impurities are generated during manufacturing, many of which are hard to identify using available analytical methods. Furthermore, the use of chemical modifications and formulations that expand the functionality and delivery capabilities of these therapeutics pose additional analytical challenges and potential risks.
As a result, the need for analytical methods that can determine the identity, purity, strength and stability of therapeutic oligonucleotides is critical for companies looking to meet the FDA’s Chemistry, Manufacturing, and Control (CMC) expectations.
In this webinar you will learn:
Who should attend:
Moderator:
Mike Auerbach
Editor-in-Chief
American Pharmaceutical Review
Presenter:
Jonathan Neidigh, PhD
Associate Director of Pharmaceutical Development
Pace Analytical Life Sciences